ExpressionBenchGene expression tools

Worked example: lung adenocarcinoma vs normal lung

Which genes change in lung adenocarcinoma, the most common lung cancer in people who have never smoked? We reanalysed a public dataset of 27 patients, each with a tumor sample and a sample of their own normal lung.

Explore the full results yourself. Open this table in the DE Results tool to see the interactive volcano plot, search for any gene and run pathway enrichment.

Open in DE Results

The study

All 27 patients had never smoked and had early-stage (stage I) adenocarcinoma. The authors sequenced DNA and RNA from each tumor and its normal lung to study mutations. We use the RNA data to ask which genes are more or less active in the tumors.

Original paper: Sun Z, Wang L, Eckloff BW and colleagues, Mayo Clinic. Conserved recurrent gene mutations correlate with pathway deregulation and clinical outcomes of lung adenocarcinoma in never-smokers. BMC Medical Genomics 2014;7:32. doi:10.1186/1755-8794-7-32. Data: GEO GSE87340.

What we compared

Every patient gave one tumor and one normal lung sample, so all 54 samples are used and each tumor is compared with the same patient's normal lung.

We used 54 samples: 27 tumors and 27 normal, from 27 patients. The read counts are NCBI's own, made with one standard pipeline for every public human dataset. The samples used and the samples left out, with reasons are listed in full.

Quality checks

Sequencing depth. Each sample had 43.9 to 119.9 million reads counted on genes (median 71.9 million), which is plenty for this kind of analysis. See the depth of every sample.

Sample map (PCA): each dot is a sample, coloured by tumor or normal. Tumors and normal samples form two separate groups.
Sample map (PCA). Each dot is one sample; samples with similar gene activity sit close together. The horizontal direction captures 43% of all variation between samples, and it separates tumors from normal tissue.

One tumor looks more like normal lung, and we kept it. The tumor sample from patient 2502 sits closer to the normal samples than to the other tumors. Its own normal sample looks normal, so this isn't a label swap. The tumor is recorded as BAC, a type that grows in a thin layer along the lung's air sacs, so the sample probably contains a lot of normal lung. That is real biology, not an error, so the sample stays in.

The label check for every sample and a sample-to-sample similarity map are available too.

Results

Volcano plot of tumor vs normal: genes higher in tumors on the right in red, lower in tumors on the left in blue.
Volcano plot made by the DE Results tool from this table (its “Download SVG” output), so it is the same plot you get by opening the example. Each dot is a gene. Right: more active in tumors (red); left: less active (blue). Higher dots have stronger evidence. The dashed lines mark a 2-fold change and an adjusted p-value of 0.05.

Of 22,585 genes tested, 14,797 differ with an adjusted p-value below 0.05. Many of those changes are small. Requiring at least a doubling or halving leaves 1,552 genes up and 2,130 down in tumors.

Strongest evidence: higher in tumors

Genelog2 fold changeAdjusted p
GCNT3+5.873.2e-124
CST1+7.543.4e-99
COL10A1+4.211.3e-92
PROM2+2.844.0e-85
ETV4+3.745.6e-74
AFAP1-AS1+4.141.5e-69
GPT2+2.431.9e-60
LINC01426+3.403.8e-60
XDH+4.181.4e-59
ADM2+3.473.7e-57

Strongest evidence: lower in tumors

Genelog2 fold changeAdjusted p
CA4-1.895.4e-127
EPAS1-2.448.9e-92
ARHGEF26-2.171.6e-91
NCKAP5-2.891.9e-85
AMOTL1-1.191.4e-80
CCDC85A-2.748.0e-78
FERMT2-1.393.0e-73
NOVA2-2.345.5e-72
RTKN2-3.344.5e-71
SH3GL3-3.574.2e-70

A log2 fold change of +1 means twice as active in tumors; -3 means one eighth as active. The tables are ordered by strength of evidence, not by size of change.

Pathways

We ran the DE Results tool's own enrichment analysis on this table, with its default settings: genes at least 2-fold changed with an adjusted p-value below 0.05, gene sets of 5 to 500 genes, and the tested genes as the background. Up and down genes are tested separately. These are the same results you get by opening the example and choosing each library.

GO Biological Process: genes higher in tumors

119 of 7,413 gene sets with FDR < 0.05. Background: 14,276 tested genes in this library, 1,001 of them higher.

Gene setGenesFoldFDR
immunoglobulin mediated immune response (GO:0016064)70 / 1218.21.7e-45
B cell mediated immunity (GO:0019724)70 / 1267.93.9e-44
lymphocyte mediated immunity (GO:0002449)72 / 1855.52.7e-32
adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains (GO:0002460)73 / 2095.02.9e-29
leukocyte mediated immunity (GO:0002443)72 / 2264.55.1e-26

Reactome: genes higher in tumors

68 of 2,095 gene sets with FDR < 0.05. Background: 9,898 tested genes in this library, 678 of them higher.

Gene setGenesFoldFDR
Classical antibody-mediated complement activation78 / 8313.79.2e-83
Scavenging of heme from plasma78 / 8812.95.2e-78
Creation of C4 and C2 activators78 / 9012.71.4e-76
FCGR activation78 / 9012.71.4e-76
Initial triggering of complement78 / 9811.68.5e-71

GO Biological Process: genes lower in tumors

505 of 7,413 gene sets with FDR < 0.05. Background: 14,276 tested genes in this library, 1,311 of them lower.

Gene setGenesFoldFDR
blood circulation (GO:0008015)90 / 3183.12.6e-19
circulatory system process (GO:0003013)103 / 4072.81.1e-18
vasculature development (GO:0001944)83 / 3053.07.1e-17
blood vessel development (GO:0001568)77 / 2882.93.7e-15
regulation of system process (GO:0044057)102 / 4502.53.7e-15

Reactome: genes lower in tumors

41 of 2,095 gene sets with FDR < 0.05. Background: 9,898 tested genes in this library, 872 of them lower.

Gene setGenesFoldFDR
GPCR ligand binding84 / 3272.97.2e-17
Class A/1 (Rhodopsin-like receptors)64 / 2333.13.8e-14
Muscle contraction54 / 1833.42.7e-13
GPCR downstream signalling100 / 4942.32.7e-13
Peptide ligand-binding receptors36 / 1353.03.4e-07

“Genes” is how many of the set's genes changed, out of all the set's genes in the background. “Fold” is how many times more changed genes the set has than expected by chance. Releases: GO Biological Process ontology release 2026-07-26, human annotations generated 2026-05-21; Reactome release 98; WikiPathways release 2026-11-10. All significant gene sets from all three libraries, with their genes: enrichment.txt. The tool's library releases are refreshed monthly, so results in the tool may differ slightly from those shown here.

What the results show

These are broad patterns that match what is already known about this cancer, which is a useful sign the analysis behaves as it should. They are not new findings.

Limits

How we ran it

DESeq2 1.50.2 in R 4.5.2 (Bioconductor 3.22), comparing tumor with normal within each patient (design ~ donor + tissue). Genes were kept if they had at least 10 reads in at least 27 samples. P-values were adjusted with the Benjamini-Hochberg method, and fold changes were shrunk with apeglm 1.32.0. Each step explained in plain words.

The volcano plot and pathway results were made by the DE Results tool itself (version 0.3), run on the results table in a browser, not by separate code.

Files: full results for every tested gene · pathway results · volcano plot (SVG) · summary · downloaded files and checksums · software versions · code: download step, analysis step and tool step. The analysis ran in a fixed Bioconductor container: ghcr.io/bioconductor/bioconductor_docker@sha256:e34177896c1579f66d48b756e4229b58237499183a089da084af72d7aba1d40a.

If you use these results, please cite the original study above. Our reanalysis may differ from the authors' own results because the read counts, filtering and statistical method differ.